Minor DR - Search Results

1

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S. Minor DR, et al. Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23. Oncologist. 2009. PMID: 19776094 Free article.

2

A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.

Minor DR, Madland MT, Kashani-Sabet M, Denny SR, Harvey WB. Minor DR, et al. Cancer Biother Radiopharm. 2005 Oct;20(5):479-86. doi: 10.1089/cbr.2005.20.479. Cancer Biother Radiopharm. 2005. PMID: 16248763

3

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Minor DR, Chin K, Kashani-Sabet M. Minor DR, et al. Cancer Biother Radiopharm. 2009 Jun;24(3):321-5. doi: 10.1089/cbr.2008.0607. Cancer Biother Radiopharm. 2009. PMID: 19538054

4

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. Weber J, et al. Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671877 Clinical Trial.

5

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Weber JS, et al. Melanoma Res. 2011 Dec;21(6):530-4. doi: 10.1097/CMR.0b013e32834d3d88. Melanoma Res. 2011. PMID: 22051508 Clinical Trial.

6

Sunitinib therapy for melanoma patients with KIT mutations.

Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Minor DR, et al. Clin Cancer Res. 2012 Mar 1;18(5):1457-63. doi: 10.1158/1078-0432.CCR-11-1987. Epub 2012 Jan 18. Clin Cancer Res. 2012. PMID: 22261812

7

Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.

Minor DR, Rodvien R, Kashani-Sabet M. Minor DR, et al. Melanoma Res. 2012 Oct;22(5):410-1. doi: 10.1097/CMR.0b013e3283573437. Melanoma Res. 2012. PMID: 22828249

8

Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.

Fadaki N, Cardona-Huerta S, Martineau L, Thummala S, Cheng ST, Bunker SR, Garcia-Kennedy R, Wang W, Minor D, Kashani-Sabet M, Leong SP. Fadaki N, et al. BMJ Case Rep. 2012 Oct 22;2012:bcr2012007034. doi: 10.1136/bcr-2012-007034. BMJ Case Rep. 2012. PMID: 23093505 Free PMC article.

9

Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.

Ruschulte H, Shi S, Tseng WW, Kolodzie K, Crawford PC, Schneider DB, Kashani-Sabet M, Minor D, Apfel C, Leong SP. Ruschulte H, et al. BMC Anesthesiol. 2013 Jul 17;13(1):15. doi: 10.1186/1471-2253-13-15. BMC Anesthesiol. 2013. PMID: 23865420 Free PMC article.

10

The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.

Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, Sun V, Tong S, Leong SP, Minor D, Billings PR, Soroceanu L, Debs R, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M. Dar AA, et al. J Natl Cancer Inst. 2015 Feb 23;107(5):djv034. doi: 10.1093/jnci/djv034. J Natl Cancer Inst. 2015. PMID: 25713167 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters